| 发明名称 |
Crystalline isoxazole derivative and medical preparation thereof |
| 摘要 |
Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2theta) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation. <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="35pt" align="left"/> <colspec colname="1" colwidth="28pt" align="center"/> <colspec colname="2" colwidth="154pt" align="center"/> <THEAD> <ROW> <ENTRY/> <entry namest="offset" nameend="2" align="center" rowsep="1"/> </ROW> <ROW> <ENTRY/> <ENTRY>2theta (°)</ENTRY> <ENTRY>Relative intensity (%)</ENTRY> </ROW> <ROW> <ENTRY/> <entry namest="offset" nameend="2" align="center" rowsep="1"/> </ROW> </THEAD> <TBODY VALIGN="TOP"> <ROW> <ENTRY/> </ROW> </TBODY> </TGROUP> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="35pt" align="left"/> <colspec colname="1" colwidth="28pt" align="char" char="."/> <colspec colname="2" colwidth="154pt" align="char" char="."/> <TBODY VALIGN="TOP"> <ROW> <ENTRY/> <ENTRY>6.1</ENTRY> <ENTRY>100</ENTRY> </ROW> <ROW> <ENTRY/> <ENTRY>14.1</ENTRY> <ENTRY>55</ENTRY> </ROW> <ROW> <ENTRY/> <ENTRY>16.0</ENTRY> <ENTRY>74</ENTRY> </ROW> <ROW> <ENTRY/> <ENTRY>18.5</ENTRY> <ENTRY>36</ENTRY> </ROW> <ROW> <ENTRY/> <ENTRY>20.0</ENTRY> <ENTRY>43</ENTRY> </ROW> <ROW> <ENTRY/> <ENTRY>25.4</ENTRY> <ENTRY>39</ENTRY> </ROW> <ROW> <ENTRY/> <entry namest="offset" nameend="2" align="center" rowsep="1"/> </ROW> </TBODY> </TGROUP> </TABLE> </TABLES>
|
| 申请公布号 |
US7429588(B2) |
申请公布日期 |
2008.09.30 |
| 申请号 |
US20030473005 |
申请日期 |
2003.09.26 |
| 申请人 |
DAINIPPON SUMITOMO PHARMA CO., LTD. |
发明人 |
OCHIAI YASUSHI;TOMOMURA KAZUHIKO;NISHII HIROYUKI |
| 分类号 |
A61K31/5377;A61P29/00;C07D261/14;C07D413/12 |
主分类号 |
A61K31/5377 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
